Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy Volunteers.

Autor: Nasser A; Supernus Pharmaceuticals, Inc., Rockville, Maryland., Randall Owen J; Navitor Pharmaceuticals, Inc., Boston, Massachusetts., Gomeni R; Pharmacometrica, Lieu-dit Longcol, La Fouillade, France., Kosheleff AR; Supernus Pharmaceuticals, Inc., Rockville, Maryland., Portelli J; Supernus Pharmaceuticals, Inc., Rockville, Maryland., Adeojo LW; Supernus Pharmaceuticals, Inc., Rockville, Maryland., Hughes TE; Navitor Pharmaceuticals, Inc., Boston, Massachusetts. Electronic address: thughes@navitorpharma.com.

Publikováno v: Clinical therapeutics [Clin Ther] 2024 Mar; Vol. 46 (3), pp. 217-227. Date of Electronic Publication: 2024 Mar 13.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.

Autor: Nasser A; Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA. anasser@supernus.com., Hull JT; Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA., Chaturvedi SA; Formerly with Supernus Pharmaceuticals, Inc. 9715 Key West Avenue, Rockville, MD, USA., Liranso T; Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA., Odebo O; Formerly with Supernus Pharmaceuticals, Inc. 9715 Key West Avenue, Rockville, MD, USA., Kosheleff AR; Formerly with Supernus Pharmaceuticals, Inc. 9715 Key West Avenue, Rockville, MD, USA., Fry N; Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA., Cutler AJ; Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA., Rubin J; Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA., Schwabe S; Formerly with Supernus Pharmaceuticals, Inc. 9715 Key West Avenue, Rockville, MD, USA., Childress A; Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA.

Publikováno v: CNS drugs [CNS Drugs] 2022 Aug; Vol. 36 (8), pp. 897-915. Date of Electronic Publication: 2022 Jul 27.

Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.

Autor: Nasser A; Supernus Pharmaceuticals Inc., Rockville, Maryland, USA., Gomeni R; Pharmacometrica, Lieu-dit Longcol, La Fouillade, France., Wang Z; Supernus Pharmaceuticals Inc., Rockville, Maryland, USA., Kosheleff AR; Supernus Pharmaceuticals Inc., Rockville, Maryland, USA., Xie L; Supernus Pharmaceuticals Inc., Rockville, Maryland, USA., Adeojo LW; Supernus Pharmaceuticals Inc., Rockville, Maryland, USA., Schwabe S; Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Dec; Vol. 61 (12), pp. 1626-1637. Date of Electronic Publication: 2021 Aug 08.

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder.

Autor: Nasser A; Supernus Pharmaceuticals, Inc., Rockville, MD, USA., Kosheleff AR; Supernus Pharmaceuticals, Inc., Rockville, MD, USA., Hull JT; Supernus Pharmaceuticals, Inc., Rockville, MD, USA., Liranso T; Supernus Pharmaceuticals, Inc., Rockville, MD, USA., Qin P; Supernus Pharmaceuticals, Inc., Rockville, MD, USA., Busse GD; Supernus Pharmaceuticals, Inc., Rockville, MD, USA., Fava M; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA., Maletic V; Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, SC, USA., Rubin J; Supernus Pharmaceuticals, Inc., Rockville, MD, USA., Lopez F; Children's Developmental Center, Winter Park, FL, USA.

Publikováno v: International journal of clinical practice [Int J Clin Pract] 2021 Aug; Vol. 75 (8), pp. e14330. Date of Electronic Publication: 2021 May 26.

Junk Food Exposure Disrupts Selection of Food-Seeking Actions in Rats.

Autor: Kosheleff AR; Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States., Araki J; Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States., Tsan L; Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States., Chen G; Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States., Murphy NP; Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States., Maidment NT; Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States., Ostlund SB; Department of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.; Department of Anesthesiology and Perioperative Care, University of California, Irvine, Irvine, CA, United States.

Publikováno v: Frontiers in psychiatry [Front Psychiatry] 2018 Aug 16; Vol. 9, pp. 350. Date of Electronic Publication: 2018 Aug 16 (Print Publication: 2018).